APA (7th ed.) Citation

N, T., HS, Y., S, Y., E, T., U, O., S, O., . . . H, O. (2026). Pan-immune-inflammation value as a prognostic and predictive biomarker in metastatic non-small cell lung cancer treated with nivolumab: A real-world study. Oncology letters, 32(3), 395. https://doi.org/10.3892/ol.2026.15750

Chicago Style (17th ed.) Citation

N, Turan, et al. "Pan-immune-inflammation Value as a Prognostic and Predictive Biomarker in Metastatic Non-small Cell Lung Cancer Treated with Nivolumab: A Real-world Study." Oncology Letters 32, no. 3 (2026): 395. https://doi.org/10.3892/ol.2026.15750.

MLA (9th ed.) Citation

N, Turan, et al. "Pan-immune-inflammation Value as a Prognostic and Predictive Biomarker in Metastatic Non-small Cell Lung Cancer Treated with Nivolumab: A Real-world Study." Oncology Letters, vol. 32, no. 3, 2026, p. 395, https://doi.org/10.3892/ol.2026.15750.